UK) is currently used to identify recent infection and to identify exposed animals without signs. This serologic test uses 2 surface protein antigens composed of N-terminal portions of SEQ_2190 (Antigen A) and SeM (Antigen C) and has the capability to differentiate vaccinates from infected animals (DIVA), depending on which vaccine is used. We hypothesize that horses vaccinated for strangles with Pinnacle IN (Zoetis), which is based on a live attenuated, non-encapsulated SeM-2 strain of S. equi, will seroconvert when tested 5 weeks after annual revaccination. Serum samples from 26 horses (mean 15.1 years)
in a stable with a strangles outbreak 11 years prior were obtained at the time of annual strangles vaccination (S1) and 5 weeks post vaccination (S2). No horses had a history of strangles and mean medical record history was 4.28 years; mean historical Pinnacle vaccines was 5. For each antigen (Ag), seroconversion was determined as an OD450nm value above 0.5. 5 out of 25 (20%) horses were seroconverted to Ag A prior to vaccination (2 of these 5 were seroconverted to both Ag A and C). 5 weeks post vaccination, 12 out of 25 (48%) were seroconverted to Ag A (mean S2 1.09) and 18 of 25 (72%) to Ag C (mean S2 1.7). With a high rate of seroconversion to both antigens, the DIVA capabilities of this iELISA 1 in horses vaccinated with Pinnacle appears poor.
References: 1 Robinson C, Steward KF, Potts N et al. Combining two serological assays optimises sensitivity and specificity for the identification of Streptococcus equi subsp. equi exposure. Vet J 2013; 197:188-191 . as the gold standard) were tested using eqbE SEQ2190 triplex qPCR with (+) and without (-) PMA pre-treatment. Number of S. equi positive samples were as follows: 6/57 eqbE + PMA, 10/57 SEQ2190 + PMA, 13/57 eqbE -PMA, 53/57 SEQ2190 -PMA. The cycle threshold count (CT) for SEQ2190 was lower than the corresponding SeeI suggesting that SEQ2190 is a good target gene. The CT for all +PMA positive samples were higher than the corresponding -PMA sample indicating there was a mixture of viable and nonviable cells in these samples. The low number of qPCR +PMA positive samples indicates that a large number of the samples had nonviable cells most likely due to storage time. PMA qPCR can be used to determine S. equi viability, but testing should be performed on fresh samples. having a hypermucovisous (HMV) phenotype, have been described in humans, non-human primates, and marine mammals. Klebsiella pneumoniae with and without the HMV phenotype were isolated from pulmonary samples from five horses in California and Alabama. All five horses were euthanized; four underwent necropsy examination where the primary pulmonary lesions were severe pneumonia, consolidation, and abscessation. Thirteen K. pneumoniae isolates with differing colony morphologies were obtained from ante-and/or post-mortem samples from the five horses. Isolates were examined for mucoviscosity using the "string test," their identity was confirmed molecularly, and their virulence gene profiles were characterized using endpoint PCR. Eleven isolates from three horses were genotyped by pulsedfield gel electrophoresis (PFGE). Six out of 13 isolates exhibited the HMV phenotype including isolates from four of the five horses. All isolates were capsular type 5 and rmpA positive regardless of HMV phenotype. PCR demonstrated identical virulence-gene profiles for all isolates. They were positive for fimH, fyuA, iroD, and mrkB and negative for the other tested virulence-associated genes. Examination of PFGE pulsotypes revealed all isolates from two horses at the same facility were indistinguishable suggesting that HMV K. pneumoniae may be capable of transmission between horses or acquired from a common source of infection. Isolates from the third horse were unrelated to the other horse isolates but indistinguishable from one another. Hypermucoviscous/hypervirulent K. pneumoniae should be considered as an etiologic agent in severe pneumonia in horses.
Identification of Enterococcus durans as a Cause of Neonatal Diarrhea on a Thoroughbred Breeding Farm
Nathan Slovis A prospective case series was undertaken to determine the association of equine parvovirus-hepatitis (EqPV-H) with Theiler';s disease.
Horses were recruited through the ACVIM listserv between January 2014-February 2018. Inclusion criteria were acute onset of clinical signs of hepatic failure and laboratory and/or liver histopathologic features characteristic of Theiler';s disease. Aliquots of serum, liver, and any biologic product administered to each case were tested for EqPV-H by qRT-PCR. Eighteen cases of Theiler';s disease had a history of biologic product administration within the prior 4 months: 12 received tetanus antitoxin, 3 received equine plasma, and 3 received allogenic stem cells. Ten cases occurred with no history of equine biologic product administration. Serum and/or liver was EqPV-H + in 27 of 28 consecutive cases. The biologic product was EqPV-H + in 10/10 cases for which aliquots were obtained. One farm with 4 non-biologicassociated cases was investigated further and 21/40 (52%) mares were EqPV-H viremic. Twenty four mares had paired serum chemistry and EqPV-H PCR. Six of 6 (100%) with active hepatitis were EqPV-H+, and 11 of 18 (61%) with normal liver enzymes were EqPV-H+.
Fourteen of 21 (66%) EqPV-H + mares were persistently infected for 1 year without clinical disease. In conclusion, 27/28 consecutive cases of Theiler';s disease were infected with EqPV-H, but infection was also common in horses with subclinical hepatitis and clinically healthy horses. These findings suggest that fulminant hepatitis is an important, but rare, outcome of EqPV-H infection. Further studies should be performed to definitively prove EqPV-H is the cause of Theiler';s disease.
Proportional Morbidity Rate (1990 Rate ( -2015 The PMR was 0.80% (2110/263,862) from 1990-2015. There was a significant decrease in PMR observed from years 2009 to 2015 of the study. Standardbreds (1.59%), Walking Horses (1.37%) and Thoroughbreds (1.31%) had significantly (P < 0.05) higher PMR compared to the PMR for all breeds. The majority (63%) of practitioners thought that the incidence of EPM had not changed (44%) or increased (19%) in the previous 2-4 years.
Other than 1996-1998, PMR for EPM in horses did not change from through 2007. However, for the past 7 years, the number of EPM cases presented to veterinary teaching hospitals has significantly decreased, noted by a significantly decreased PMR. This was in contrast to the practitioners'; perceptions where a majority thought cases were staying the same or increasing. Also, it appears that Standardbreds, Walking Horses and Thoroughbred and geldings are more likely to be diagnosed with EPM. The data suggest that practitioners are treating EPM in the field and fewer cases are being referred to veterinary teaching hospitals. However, the data should be interpreted with caution as reporting of EPM cases through the VMDB is dependent on the veterinary teaching hospitals. Concurrent eosinophilic inflammation affecting a separate organ was found in only 2 horses with mild EAD, and 6 with moderate-severe EAD. Fecal shedding of strongyle ova was low in all EAD horses.
Symmetric Dimethylarginine and Creatinine Concentrations in
Eosinophilic airway disease was common among horses with clinical signs of respiratory disease in this study (31%). Moderate-to-severe EAD is associated with mastocytic airway inflammation and peripheral eosinophilia, and can occur in the absence of other organ involvement.
Interstitial lung pathology can be identified radiographically and histopathologically.
Safety and Efficacy of Canagliflozin and Octreotide for Managing Insulin Dysregulation in Horses
Nicholas Frank Tufts University, North Grafton, MA, USA Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used to control diabetes mellitus in humans and octreotide is a somatostatin analog prescribed for the treatment of acromegaly. We hypothesized that canagliflozin and octreotide would significantly alter glucose and insulin concentrations in horses with insulin dysregulation (ID), without negatively impacting their health.
Six horses with ID received canagliflozin and octreotide for 3 days at three dosage levels, according to a crossover design. Plasma glucose and insulin concentrations were measured and an oral sugar test (OST) was performed prior to the first dose, and 24 hours after the third dose of drug was administered. No adverse health outcomes were detected. Both drugs caused insulin concentrations to decrease immediately following administration. When pre-and post-treatment OST area under the insulin curve (AUCi) values were compared, they did not change significantly at the low canagliflozin dosage level (P = 0.110), but significantly decreased with canagliflozin treatment at the medium (P = 0.094) and high (P = 0.019) dosage levels. Octreotide pre-and post-treatment AUCi values did not differ significantly at the low (P = 0.507) or medium (P = 0.222) dosage levels, but significantly increased with treatment at the high (P = 0.020) dosage level.
Octreotide transiently lowers insulin concentrations in horses with ID, but has only a short duration of action. We provide evidence that canagliflozin improves insulin dynamics in horses with ID after administration of only 3 doses and this drug warrants further investigation as a strategy for preventing laminitis. 6 healthy adult horses received 500 mL 0.9% saline infused IV over 15 minutes containing 2, 3, or 4 mmol/kg BWT (Dose) NaLAC, resulting in a range of 1200 to 2600 mEq total Na and LAC administered.
Blood (B) and urine (U) were sampled prior to infusion (Time 0), then at 15, 30, 45, 60, 90, and 120 Overall, serum and UNa were unrelated (P = 0.526) with blood LAC and ULAC trending toward a small positive association (P = 0.059). USG, affected by Na load, impacts assessment of ULAC:Ucr and UNa: cr, potentially limiting NaLAC challenge studies using concentrations >2mmol/kg bodyweight.
Pharmacokinetics, Dose Proportionality of Escalating Dosages of Gabapentin in Adult Horses
Jenifer R. Washington State University, Pullman, WA, USA Neuropathic pain, as can occur in laminitis, is largely refractory to standard analgesic drugs but may be controlled with the drug gabapentin. In humans, gabapentin undergoes non-proportional pharmacokinetics which can alter safety and efficacy. There is no information on the pharmacokinetics of escalating dosages or on dose proportionality of gabapentin in horses.
In a single blinded randomized cross-over study using 10 adult horses receiving gabapentin administered by nasogastric tube, 3 horses received 10, 20, 40 mg/kg and 6 horses received 60, 80, 120, 160 mg/kg. Plasma was collected at pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 16, 32 and 64 hours post administration of gabapentin. All horses had a 2-week washout period between doses. Gabapentin was quantified in plasma using a validated chromatographic method. Pharmacokinetic parameters were estimated using non-compartmental analysis.
Pharmacokinetic parameters are presented in table 1. Computer simulation of the disposition of gabapentin following multi-dose oral administration predicts accumulation of gabapentin in plasma when given every 8 or 12 hs. Steady state is likely to be reach after 3 days (2000) 170000 ( bacterial antigens (P < 0.05). In addition, PMNs isolated from UNS calves had a greater ability to phagocytose E. coli and S. aureus when compared to STR calves. Serum non-esterified fatty acids (NEFA) were significantly higher in STR calves (P < 0.01). Serum β-hydroxybutyrate (BHB) was significantly lower in STR calves (P < 0.01). These data suggest that immunologic and physiologic differences exist between STR The goals of this study were to compare the efficacies of tulathromycin to enrofloxacin in cattle at high-risk of developing BRD, and the prevalence of MDR strains of M. haemolytica before and after metaphylactic administration of each drug. Stocker calves (n=341) were randomly assigned to 2 treatment groups: enrofloxacin (n=172) and tulathromycin (n=169). 33.7% of calves receiving enrofloxacin required treatment for BRD within 45 days after arrival, compared to 18.3% of calves receiving tulathromycin. The odds of being diagnosed with BRD were 58% lower for calves receiving tulathromycin compared to those receiving enrofloxacin (P = 0.040). 10.5% of calves receiving enrofloxacin required more than one treatment, compared to 4.7% of calves receiving tulathromycin. The odds of requiring a second treatment were 60% lower for calves receiving tulathromycin compared to those receiving enrofloxacin. (P = 0.107). 12.2% of calves receiving enrofloxacin died during the 45-day follow-up period, compared to 10.1% of calves receiving tulathromycin (P = 0.592). In calves receiving enrofloxacin, M. haemolytica was cultured from 11.4% of calves sampled at arrival, and from 54.6% sampled at revaccination.
In calves receiving tulathromycin, M. haemolytica was cultured from 10.8% of calves sampled at arrival, and from 48.7% sampled at revaccination. There was a significant effect of sampling occasion (P < 0.001) with both groups having higher prevalences of M. haemolytica at revaccination than at arrival. All calves in both groups had MDR strains at the time of revaccination, with the prevalence being significantly (P < 0.000) higher than at arrival. In conclusion, comet-tails and lung consolidation had acceptable agreements between operators with various levels of TUS expertise. We first validated a portable lactate meter that requires very small sample volumes for analysis of canine blood and then subsequently for canine CSF. We developed a reference interval for canine CSF (1.0-2.5 mmol/l). This analyzer was then used for the evaluation of CSF samples in dogs with a variety of CNS disorders.
Pharmacokinetics of Tulathromycin in Healthy Goats

NEUROLOGY
We have analyzed approximately 500 canine CSF samples to date. Dogs with meningoencephalitis or meningomyelitis were most likely to have an increased CSF lactate concentration. Samples with confirmed or suspected bacterial meningitis showed elevated concentrations although many other non-infectious inflammatory samples were similarly elevated. The mean CSF lactate concentrations for CNS disorders grouped into broad categories were: inflammatory disease 3.1 mmol/l, neoplastic disease 2.4 mmol/l, vascular accidents 2.2 mmol/l, and intervertebral disk disease 2.1 mmol/l. Seizure activity did not seem to influence CSF lactate concentrations. This analyzer is useful for the rapid analysis of lactate in canine CSF.
Elevations in CSF lactate were most frequently attributable to an inflammatory CNS condition, which may aid clinicians in deciding on acute interventions for these patients. Spinal spreading of brain gliomas is a rare condition in human medicine that was never described in dogs. Further studies could highlight if the stereotactic irradiation could promote the spinal spreading of loosely arranged neoplastic cells of superficial oligodendrogliomas. The purposes of this study were to compare serum phenobarbital (S-PB) concentrations and caregiver satisfaction at steady-state after oral (PO) and transdermal (TD) administration of phenobarbital (PB) in epileptic cats. Nine cats were enrolled in this prospective cohort study.
Progression of Vertebral and Spinal Cord Changes in Dogs with
Comparison of Serum Phenobarbital Concentrations After Chronic Oral and Transdermal Phenobarbital Administration in Epileptic Cats
Cats received PO-PB for 14 weeks, followed by TD-PB for 14 weeks.
Although steady-state blood concentrations were expected by day 14, the trial was continued over 14 weeks for each phase to observe caregiver satisfaction. Clients completed a questionnaire at 14 and 28 weeks. The median oral PB dosage was 4.2 mg/kg/day divided q12h (2.0 -6.0 mg/kg) and the median S-PB concentration was 22 mcg/ml (8.0-35.0 mcg/ml). The median starting TD-PB dosage was 18.7 mg/kg/day divided q12h (17.5-24.0 mg/kg/day) and first steadystate TD S-PB concentrations were 18 mcg/ml (0-42.0 mcg/ml). One cat did not have detectable S-PB concentrations. TD S-PB concentrations were within 10% of final PO S-PB concentrations. (p = 0.17) Administration was designated "easy" for PO and TD phases, 44% and 78% of the time, respectively. However, there was no significant difference in preference between the two routes of administration.
(p = 0.13) The results of this study indicate steady-state S-PB concentrations were achieved in 8 of 9 cats following both transdermal and oral administration and that caregivers reported a 34% greater ease of administration with the transdermal formulation. The maximal serum CO concentration was 575.3 ± 109.6 ng/mL at 112 ± 36.7 h. The maximal serum Ara-C concentration was 635.7 ± 140.5 ng/mL at 36.7 ± 58.3 h. CO was not detected in the CSF until 144 hours in one dog, and until 180 hours in two dogs, while Ara-C was detected at 24 hours in all dogs. All dogs became leukopenic after receiving 7 doses of CO (144 h). The maximal concentration of Ara-CTP detected in leukocyte DNA at 168 ± 41.6 h.
Serum Ara-C concentrations following CO administration were lower than those reported following parenteral Ara-C administration. Both CO and Ara-C were able to enter the CSF. Peripheral blood leukocyte concentrations decreased significantly following the administration of CO, and Ara-CTP accumulated within leukocyte DNA.
Individualized analysis of therapy for chronic spinal cord injury in dogs
Nick Jeffery 1 , Nicolas Granger 2 , Unity Jeffery All outcome assessment methods contain inherent variability, owing to errors in measurement and differences within and between individuals. These can be analyzed in untreated animals, using methods derived from laboratory medicine, and then combined to define boundaries of outcome beyond which 'real change'; attributable to the intervention can be inferred.
In both of two recent clinical trials of putative therapies for chronic spinal cord injury in companion dogs there were interventionassociated benefits at a group level. The data from untreated controls were re-analyzed as described above, which identified 2 of 23 recipients of intraspinal olfactory ensheathing cells and 2 of 27 dogs that received intraspinal chondroitinase as unequivocal responders. There were no specific pre-trial clinical characteristics in common amongst these dogs except that all became paralyzed following intervertebral disc herniation (not fracture-luxation).
This responder rate (4/50 cases overall) corresponds to a numberneeded-to-treat (NNT) of 12.5. Although this NNT appears high, it is comparable to those associated with many commonly used drugs and the treated condition is extremely severe and has no other available therapy.
This analysis confirms the efficacy of these two interventions in severe chronic spinal cord injury in dogs, defines a responder rate and, although not successful here, provides a method to identify prognostic factors for response to therapy. The goal of cancer treatment for dogs is to increase survival while providing good quality of life (QOL). In a prospective, blinded, randomized, controlled study, we investigated whether a novel dry diet with increased protein and antioxidants, a custom fiber blend, and EPA and DHA would improve QOL compared to a typical maintenance diet in dogs undergoing chemotherapy for lymphoma (LSA) and mast cell tumors (MCT).
Influence of Duration of Injury on Diffusion Tensor Imaging in
Twenty-one chemotherapy-naïve client-owned dogs (16 LSA, 5 MCT)
were enrolled in the maintenance diet group and 24 (17 LSA, 7 MCT) in the test diet group. The dogs ate the diets for 8 weeks while being treated with standardized chemotherapy protocols specific for each tumor type at five study sites. Dog owners evaluated QOL at baseline and after 8 weeks using a previously published questionnaire designed for dogs with cancer. Data was analyzed using 'intent to treat'; principles.
There were no significant differences in dog or tumor parameters between diet groups at baseline other than body weight; dogs on the test diet weighed more than dogs on the maintenance diet The results of this study suggest that the use of a liquid fiducial to create a planning target volume for SRS delivery is very safe, with minimal acute and delayed toxicity observed. Additionally, all patients injected with fiducial had easily identifiable markers present that could be used both for CTV/PTV creation and for treatment alignment purposes using the cone beam CT of the linear accelerator. Based on these results, the trial has expanded to focus on long-term outcomes and toxicity analysis based on specific tumor types. Following administration of MCWF, all animals were closely monitored for 2h in the clinic before being sent home with the owner.
Phase-I Clinical
Temperature, blood pressure, heart and respiratory rate were assessed every 30-45 min. In addition, whole blood samples were taken every two to four weeks and complete blood counts and clinical chemistry analysis were performed.
Adverse events (AE';s) were observed in 5 animals and were considered minimal. Observed AE';s included mild lethargy (8) Blood and exam parameters were collected weekly for 4 weeks, monthly for 1 year, then q2-3 months. Thoracic radiographs were performed every 3 months. Quality of life and symptoms were measured at each visit using validated questionnaires. Dogs were followed until death and underwent necropsy.
14 dogs (mean age 9.0 ± 1.9 years, mean weight 29.7 ± 6.9 kg) were enrolled. Mean starting toceranib dose was 2.66 ± 0.9 mg/kg; mean treatment duration was 311 ± 188 days. Dose reductions and temporary treatment breaks each occurred in 7/14 dogs, and 11/14 dogs received metronidazole or Denamarin to manage low grade diarrhea or liver enzyme elevations, respectively. Two dogs had serious adverse events that could have been related to treatment. Median progression free and overall survival times were 310 days (95% CI 81-462) and 406 days (95% CI 121-556), respectively. Metastatic osteosarcoma was confirmed histopathologically in 12 dogs; 2 had no metastasis at death. Owners consistently rated quality of life as good to excellent throughout treatment, although ratings were sometimes lower during periods of adverse clinical signs.
Combination amputation and oral toceranib was associated with acceptable quality of life and survival and could be a beneficial adjuvant treatment when intravenous chemotherapy is unavailable or refused by owners. The aim of this study was to develop culture protocols for duodenum, jejunum, ileum and colon ENT/COL from healthy dogs (n=23) and dogs with chronic enteropathies (CE) (n=12). In addition, we sought to extensively characterize the cells within ENT/COL using bright field imaging, transmission electron microscopy, immunohistochemistry, RNA in situ hybridization, and RNA microarray. Functional assays were developed using a 2D transwell culture approach for stimulation assays and optical metabolic imaging (OMI) for 3D cultures in matrigel.
SMALL ANIMAL INTERNAL MEDICINE
Organoids were cryopreserved for the development of a canine ENT/COL bioarchive.
Ten endoscopic biopsies per intestinal region were acquired from healthy or CE dogs. Minced samples were repeatedly washed. Crypts were enriched, using EDTA chelation, released via trituration, embedded in matrigel, and grown in intestinal stem cell media.
Organoid yield was 5 enteroids/biopsy and 30 colonoids/biopsy on average. Optimized intestinal stem cell growth media for proliferation versus differentiation contained rho-associated kinase ROCK inhibitor Y27632, glycogen synthase kinase 3β inhibitor CHIR99021, and wnt- (GUE) . In studies in dogs and cats, omeprazole has been shown to be more effective at raising gastric pH and it is now recommended for GUE treatment. However, famotidine continues to be widely used by veterinary practitioners especially for conditions in which potent acid suppression is not desired. In dogs and humans, the acid suppressing effect of famotidine decreases over time, often within 1-2 weeks. Every other day (EOD) famotidine administration might prevent the induction of tolerance. Our study objectives were to determine if (1) daily famotidine administration leads to tolerance in cats, and, (2) EOD administration prevents the induction of tolerance. In a randomized, crossover study, 16 cats received 1 mg/kg famotidine orally q12h daily or twice-daily EOD for 2 weeks. Intragastric pH was compared on treatment days 1 and 13 within and between treatments using Repeated Measures Mixed Effects ANOVA. Continued famotidine administration resulted in a significant decrease in mean pH, (mean percentage time) MPT intragastric pH was ≥ 3, and MPT intragastric pH was ≥ 4 (P ≤ 0.01) on treatment day 13 as compared to day 1 when cats received daily famotidine but not when they received it EOD. This resulted in a mean decrease in pH by 1.3 on day 13 com- lence of post-treatment azotemia was significantly higher (P < 0.0001) in the cats with overt (50%) and subclinical (36.5%) hypothyroidism than in the cats that remained euthyroid (11.5%) after radioiodine treatment.
In conclusion, our novel algorithm for calculating individual 131 I doses based on serum thyroid hormone concentrations, thyroid scintigraphy (thyroid tumor volume and percent TcTU), and radioiodine uptake by the thyroid tumor resulted in "cure rates" similar to historical rates, but dramatically reduced the incidence of overt and subclinical hypothyroidism. Importantly, the lower calculated radioiodine doses (compared to those currently administered by most other protocols), limit radiation exposure to veterinary staff and owners. Finally, by lowering the incidence of iatrogenic hypothyroidism, this individualized approach also lowers the rate of azotemia that develops after radioiodine treatment. Glucagon, norepinephrine, epinephrine and cortisol responses to IIH were studied 13 dogs with naturally occurring DM and 6 healthy controls. Dogs were fasted overnight and, in diabetics, insulin was withheld for 12 hours before the study. Hypoglycemia was induced by an intravenous infusion of regular porcine insulin (5 mU/kg/min) and clamped at (mean ± SD) 41.4 ± 3.5 mg/dL using a variable rate glu- Treatment of hyperthyroidism in cats is frequently associated with unmasking of pre-existing chronic kidney disease. Currently, there is no renal biomarker that can reliably predict the development of azotemia that occurs secondary to decreases in glomerular filtration rates (GFR) following treatment for hyperthyroidism. S-dimethylarginine (SDMA) has been shown to be a sensitive marker of GFR in veterinary medicine that is not influenced by changes in muscle mass. We hypothesized that SDMA could be a cost-effective and useful biomarker for prediction of decreases in total GFR and the onset of azotemia in cats receiving I-131 therapy.
Cats (n=7) diagnosed with hyperthyroidism based on clinical signs and increased serum total T4 (TT4) were included in this prospective clinical trial. Study design included a physical exam, complete blood count, serum chemistry, total T4, urinalysis and SDMA prior to treatment and at 1 and 3 months post-treatment. In addition, GFR was quantified by renal scintigraphy (Tc99mDTPA) immediately prior to and at 3 months post-treatment.
Currently, 6 of 7 cats enrolled in the trial have completed diagnostic evaluation at all three time points. The median age of the cats was 12.6 years (range 11.2 -15.2 years) and comprised 4 neutered males and 3 spayed females. All cats were non-azotemic at enrollment (creatinine < 1.6 mg/dl). The mean TT4 decreased significantly at one and three months post-treatment (p < 0.05). Five cats were euthyroid and 1 cat was hypothyroid at three months post-treatment. Mean total GFR (p < 0.05) and mean serum creatinine (p < 0.01) decreased and increased significantly between time points, respectively. Mean serum SDMA did not differ significantly from baseline at 1 (p = 0.27) or 3 (p = 0.22) months post-treatment. No significant correlation was
